CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 453 enrolled
Drug / intervention
Insulin degludec/liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03175120
NCT03175120Phase 3Completed
CompareCT.gov

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD

Novo Nordisk A/S·interventional·Posted Jun 5, 2017·Updated Mar 19, 2020

In Brief

A Phase 3 clinical trial evaluating Insulin degludec/liraglutide and Insulin degludec for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 453 participants across 37 sites in 2 countries.

Detailed Summary

This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26 weeks of treatment

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesChina, Hong Kong
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJun 5, 2017
Enrollment StartMay 26, 2017
Primary CompletionMar 5, 2019
Study CompletionApr 4, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.1 years ago

Interventions

Insulin degludec/liraglutidedrug

Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.

Insulin degludecdrug

Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.